Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development

Author(s): Komal Thapa, Ajmer Singh Grewal*, Neha Kanojia, Lata Rani, Neelam Sharma, Sukhbir Singh

Journal Name: Current Drug Discovery Technologies

Volume 18 , Issue 3 , 2021

Become EABM
Become Reviewer
Call for Editor


Alcoholic and non-alcoholic fatty liver diseases have become a serious concern worldwide. Both these liver diseases have an identical pathology, starting from simple steatosis to cirrhosis and, ultimately to hepatocellular carcinoma. Treatment options for alcoholic liver disease (ALD) are still the same as they were 50 years ago which include corticosteroids, pentoxifylline, antioxidants, nutritional support and abstinence; and for non-alcoholic fatty liver disease (NAFLD), weight loss, insulin sensitizers, lipid-lowering agents and anti-oxidants are the only treatment options. Despite broad research in understanding the disease pathophysiology, limited treatments are available for clinical use. Some therapeutic strategies based on targeting a specific molecule have been developed to lessen the consequences of disease and are under clinical investigation. Therefore, focus on multiple molecular targets will help develop an efficient therapeutic strategy. This review comprises a brief overview of the pathogenesis of ALD and NAFLD; recent molecular drug targets explored for ALD and NAFLD that may prove to be effective for multiple therapeutic regimens and also the clinical status of these promising drug targets for liver diseases.

Keywords: Alcoholic liver disease, apoptosis signal‐regulating kinase 1, farnesoid X receptor, Micro RNAs, fibroblast growth factors, non-alcoholic fatty liver disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 20 May, 2021
Page: [333 - 353]
Pages: 21
DOI: 10.2174/1570163817666200121143959
Price: $65

Article Metrics

PDF: 28